Raltitrexed based transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a single-center randomized controlled study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16007912

Enrollment

Unknown

Registered

2016-02-13

Start date

2013-11-03

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

Raltitrexed Group:TACE (raltitrexed, epirubicin and oxaliplatin)

Control Group:TACE (epirubicin and oxaliplatin)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Unresectalbe disease by surgery or other local therapies; 2. Aged between 18 and 75 years; 3. Adequate hematologic, hepatic and renal function; 4. BCLC system classifications B and C; 5. ECOG performance status 0–2.

Exclusion criteria

Exclusion criteria: 1. Severe underlying cardiac or renal diseases; 2. Secondary malignancy; 3. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Overall Survival;	—

Countries

China

Contacts

Public ContactLi Jiaping

jpli3s@126.com+86 13352890908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026